PF-05082566 (4-1BB agonist)

**FACT SHEET**

PF-05082566 is an investigational agent and has not been approved by regulatory agencies.

### ABOUT PF-05082566

PF-05082566 (PF-2566) is an investigational immunotherapy and fully humanized monoclonal antibody (mAb) administered intravenously that stimulates signaling through 4-1BB (CD-137), a protein expressed in many immune cells.

### MECHANISM OF ACTION

The 4-1BB (CD-137) protein receptor is found on T cells such as CD8+ T cells, natural killer cells and CD4+ T cells.\(^1,2\)

![Diagram of 4-1BB receptor and immune cells]

Based on pre-clinical data, when PF-2566 binds to 4-1BB, it stimulates and increases the number of immune cells.\(^1\) This may provide enhanced anti-tumor immune function.\(^1\) This is different from checkpoint inhibitors (i.e. PD-1, PD-L1), which act on another immune signaling pathway and are believed to work by inhibiting suppression of T-cells.\(^3\)

### THE POTENTIAL OF A COMBINATION APPROACH

Preclinical studies suggest that combining PF-2566 with a checkpoint inhibitor, such as anti-PD-L1, or other immunotherapies may be able to amplify the immune response.\(^4,5,6\)

Further understanding the biology of how the immune system attacks tumors and ways by which tumors evade the immune system may lead to a variety of promising combinations in the future.

### CLINICAL STUDIES

Pfizer is exploring the potential of PF-2566 in a clinical development program to determine: (a) the maximum tolerated dose (b) efficacy and (c) therapeutic potential in combination with other therapies.

Data from a Phase 1 study that evaluated PF-2566 (4-1BB) in combination with rituximab in patients with relapsed or refractory CD20+ Non-Hodgkin’s Lymphoma (NHL) presented at the 2015 ASCO Annual Meeting showed that 4-1BB demonstrated anti-tumor activity.\(^7\)

- No dose-limiting toxicities were observed and no patients discontinued treatment due to treatment-related AEs. These results characterize the potential efficacy for this investigational immunotherapy when used in combination with a drug such as rituximab that has a different MOA.\(^7\)

Pfizer will further explore 4-1BB in order to better understand its efficacy and safety when used as both a single agent and when used in combination with other anti-cancer therapies, including immunotherapies.
For more information, please visit www.pfizercancertrials.com or www.clinicaltrials.gov or call toll-free 1-877-369-9753 (in the United States and Canada) or +1-646-277-4066 (outside of the United States and Canada).

_____________________


